HER3 in NSCLC " Navigating New Frontiers in Targeted Therapy

In patients with non-small cell lung cancer (NSCLC), human epidermal growth factor receptor 3 (HER3) is associated with both advanced disease and resistance to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI)"directed therapies. Although there are therapeutic options targeting EGFR (HER1) and HER2, the potential of HER3 as an anti-cancer target has been largely overlooked. Overexpression of HER3 in most patients with NSCLC positions it as an appealing therapeutic target, especially for individuals who have shown progression following EGFR-TKI treatment, as these patients have limited alternatives beyond cytotoxic chemotherapy.

This monograph reviews the rationale for utilizing HER3 as a novel biomarker and the latest safety and efficacy data of HER3-targeted therapies. The authors discuss how these agents may fit into existing treatment paradigms and highlight optimal use through clinical case discussions, aiming to educate oncology providers on integrating HER3-targeted agents into personalized treatment plans, ultimately improving outcomes for patients with advanced NSCLC.